Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
The product will be launched in Q1FY26
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
Padmanabhan brings over two decades of extensive experience in FMCG sector
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
The supply of these goods is set to commence within the first quarter of FY26
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Subscribe To Our Newsletter & Stay Updated
